21st Century Cardio-Oncology
Cardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than conventional therapies, has revolutionized oncology therapy an...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-08-01
|
| Series: | JACC: Basic to Translational Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452302X16300559 |
| _version_ | 1818562495048056832 |
|---|---|
| author | Calvin Chen Sheng, MD Laleh Amiri-Kordestani, MD Todd Palmby, PhD Thomas Force, MD Charles C. Hong, MD, PhD Joseph C. Wu, MD, PhD Kevin Croce, MD, PhD Geoffrey Kim, MD Javid Moslehi, MD |
| author_facet | Calvin Chen Sheng, MD Laleh Amiri-Kordestani, MD Todd Palmby, PhD Thomas Force, MD Charles C. Hong, MD, PhD Joseph C. Wu, MD, PhD Kevin Croce, MD, PhD Geoffrey Kim, MD Javid Moslehi, MD |
| author_sort | Calvin Chen Sheng, MD |
| collection | DOAJ |
| description | Cardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than conventional therapies, has revolutionized oncology therapy and dramatically changed cancer prognosis. However, some of these therapies have introduced an assortment of cardiovascular (CV) complications. At times, these devastating outcomes have only become apparent after drug approval and have limited the use of potent therapies. There is a growing need for better testing platforms, both for CV toxicity screening and for elucidating mechanisms of cardiotoxicities of approved cancer therapies. This review discusses the utility of available nonclinical models (in vitro, in vivo, and in silico) and highlights recent advancements in modalities like human stem cell-derived cardiomyocytes for developing more comprehensive cardiotoxicity testing and new means of cardioprotection with targeted anticancer therapies. |
| first_indexed | 2024-12-14T01:04:29Z |
| format | Article |
| id | doaj.art-6158e6de3f1f4ac5ad684e83913463ba |
| institution | Directory Open Access Journal |
| issn | 2452-302X |
| language | English |
| last_indexed | 2024-12-14T01:04:29Z |
| publishDate | 2016-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JACC: Basic to Translational Science |
| spelling | doaj.art-6158e6de3f1f4ac5ad684e83913463ba2022-12-21T23:23:03ZengElsevierJACC: Basic to Translational Science2452-302X2016-08-011538639810.1016/j.jacbts.2016.05.00821st Century Cardio-OncologyCalvin Chen Sheng, MD0Laleh Amiri-Kordestani, MD1Todd Palmby, PhD2Thomas Force, MD3Charles C. Hong, MD, PhD4Joseph C. Wu, MD, PhD5Kevin Croce, MD, PhD6Geoffrey Kim, MD7Javid Moslehi, MD8Cardiovascular Division, Vanderbilt University School of Medicine, Nashville, TennesseeCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, White Oak, MarylandCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, White Oak, MarylandCardiovascular Division, Vanderbilt University School of Medicine, Nashville, TennesseeCardiovascular Division, Vanderbilt University School of Medicine, Nashville, TennesseeCardiovascular Division, Department of Medicine, Stanford University School of Medicine, Stanford, CaliforniaDivision of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MassachusettsCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, White Oak, MarylandCardiovascular Division, Vanderbilt University School of Medicine, Nashville, TennesseeCardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than conventional therapies, has revolutionized oncology therapy and dramatically changed cancer prognosis. However, some of these therapies have introduced an assortment of cardiovascular (CV) complications. At times, these devastating outcomes have only become apparent after drug approval and have limited the use of potent therapies. There is a growing need for better testing platforms, both for CV toxicity screening and for elucidating mechanisms of cardiotoxicities of approved cancer therapies. This review discusses the utility of available nonclinical models (in vitro, in vivo, and in silico) and highlights recent advancements in modalities like human stem cell-derived cardiomyocytes for developing more comprehensive cardiotoxicity testing and new means of cardioprotection with targeted anticancer therapies.http://www.sciencedirect.com/science/article/pii/S2452302X16300559cardio-oncologycardiotoxicitynonclinical modelpre-clinical model |
| spellingShingle | Calvin Chen Sheng, MD Laleh Amiri-Kordestani, MD Todd Palmby, PhD Thomas Force, MD Charles C. Hong, MD, PhD Joseph C. Wu, MD, PhD Kevin Croce, MD, PhD Geoffrey Kim, MD Javid Moslehi, MD 21st Century Cardio-Oncology JACC: Basic to Translational Science cardio-oncology cardiotoxicity nonclinical model pre-clinical model |
| title | 21st Century Cardio-Oncology |
| title_full | 21st Century Cardio-Oncology |
| title_fullStr | 21st Century Cardio-Oncology |
| title_full_unstemmed | 21st Century Cardio-Oncology |
| title_short | 21st Century Cardio-Oncology |
| title_sort | 21st century cardio oncology |
| topic | cardio-oncology cardiotoxicity nonclinical model pre-clinical model |
| url | http://www.sciencedirect.com/science/article/pii/S2452302X16300559 |
| work_keys_str_mv | AT calvinchenshengmd 21stcenturycardiooncology AT lalehamirikordestanimd 21stcenturycardiooncology AT toddpalmbyphd 21stcenturycardiooncology AT thomasforcemd 21stcenturycardiooncology AT charleschongmdphd 21stcenturycardiooncology AT josephcwumdphd 21stcenturycardiooncology AT kevincrocemdphd 21stcenturycardiooncology AT geoffreykimmd 21stcenturycardiooncology AT javidmoslehimd 21stcenturycardiooncology |